![](https://endpts.com/wp-content/uploads/2017/06/shutterstock_635798789-1.jpg)
J&J boasts improved cardio safety with SGLT2 franchise drug Invokana
J&J scored vitally important cardio safety data for its SGLT2 diabetes drug Invokana in a large Phase III outcomes study, which it happily shared with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.